Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell mediated immunity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    55 result(s) found for: Cell mediated immunity. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-004541-33 Sponsor Protocol Number: immvzmpr1 Start Date*: Information not available in EudraCT
    Sponsor Name:Västra Götalandsregionen
    Full Title: A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer.
    Medical condition: This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated ...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004240-30 Sponsor Protocol Number: AIT-MULTIVIR-01 Start Date*: 2014-06-18
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Prospective, open-label, randomised, two-arm, controlled, multicentre clinical trial, phase I/IIa, for the evaluation of safety and efficacy of an adoptive immunotherapy with allogeneic CMV-/EBV-sp...
    Medical condition: Immune deficiency after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021428 - Immune system disorders 10007877 Cell-mediated immune deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003573-42 Sponsor Protocol Number: 232100-0131 Start Date*: 2014-11-11
    Sponsor Name:Västra Götalandsregionen
    Full Title: Antibody-mediated immune response after immunization with FSME-Immun(R) against Tick Borne Encephalitis(TBE) after hematopoietic autologous and allogeneic stem cell transplantation.
    Medical condition: Patients have undergone allogeneic or autologous stem cell transplantation for hematological malignancies.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004099-31 Sponsor Protocol Number: 116811 Start Date*: 2016-07-26
    Sponsor Name:Glaxosmithkline Biologicals
    Full Title: Long-term persistence of immunity to hepatitis B in adults vaccinated 20 to 30 years ago with Engerix™-B.
    Medical condition: Healthy volunteers (immunisation against infection caused by all known subtypes of hepatitis B virus).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001819-36 Sponsor Protocol Number: Sci-B-Vac–001 Start Date*: 2018-02-02
    Sponsor Name:VBI Vaccines Inc.
    Full Title: A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
    Medical condition: Hepatitis B vaccination in healthy adults
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10054181 Hepatitis B immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002928-41 Sponsor Protocol Number: Immunity_TBE Start Date*: 2013-01-14
    Sponsor Name:Med. Uni. Wien, Klinik für Innere I
    Full Title: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study
    Medical condition: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study Study group consists of patients 11...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011152-22 Sponsor Protocol Number: GTG003.08 Start Date*: Information not available in EudraCT
    Sponsor Name:GENETHON
    Full Title: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome
    Medical condition: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome. An open labelled, non-randomised, phase I/II, cohort study involving a single infusion of autolo...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000684-16 Sponsor Protocol Number: 03MI10 Start Date*: 2010-01-21
    Sponsor Name:Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health
    Full Title: Gene therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector.
    Medical condition: X-Linked severe combined Immunodeficiency (SCID-X1)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010099 Combined immunodeficiency LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-023791-63 Sponsor Protocol Number: V70_34 Start Date*: 2011-03-24
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of Fluad® or Agrippal® in Previously Unva...
    Medical condition: influenza
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022000 Influenza LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001815-21 Sponsor Protocol Number: 212340 Start Date*: 2019-10-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIB, open label, long term follow-up study to assess persistence of immune responses to GSK’s HZ/su vaccine 4-7 years after primary vaccination; and immunogenicity and safety assessment of...
    Medical condition: Herpes Zoster
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017141-58 Sponsor Protocol Number: V111_06TP_OPERA Start Date*: 2009-11-19
    Sponsor Name:OPERA SRL
    Full Title: An Open-Label Exploratory Clinical Study to Evaluate the Antibody and Cell Mediated Immunity of One Intramuscular Dose of MF59-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovale...
    Medical condition: Prophylaxis of A/H1N1sw influenza
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022001 Influenza (epidemic) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000592-27 Sponsor Protocol Number: 13102014 Start Date*: 2015-06-18
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Immunodeficiency in cartilage-hair hypoplasia: sub-project on safety of vaccination against chickenpox
    Medical condition: Cartilage-hair hypoplasia patients.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003261-18 Sponsor Protocol Number: VITAL Start Date*: 2019-11-22
    Sponsor Name:
    Full Title: The effects of allergen immunotherapy on anti-viral immunity in patients with allergic asthma
    Medical condition: Allergic asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-002712-25 Sponsor Protocol Number: V101P1 Start Date*: 2007-10-29
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG
    Full Title: A Phase II, Randomized, Placebo-controlled, Observer-blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (containing both interpandemic strains and ...
    Medical condition: Avian Influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004726-28 Sponsor Protocol Number: ILIT2Linköping-Jönköping Start Date*: 2014-01-10
    Sponsor Name:Allergy Centre
    Full Title: Double-blind randomised controlled study to down regulate allergic responses in adults with allergic rhinoconjunctivitis by using three intralymphatic injections of grass and/or birch allergen one ...
    Medical condition: Allergic rhinoconjunctivitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005203-33 Sponsor Protocol Number: V87P3 Start Date*: 2006-11-16
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG
    Full Title: A Phase II, Multicenter, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adults Unprimed and Primed with MF59-adjuvanted or Non-adjuvanted H5...
    Medical condition: avian influenza
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003369-24 Sponsor Protocol Number: ILIT-3L Start Date*: 2017-01-03
    Sponsor Name:Allergy Centre
    Full Title: Double-blind randomised controlled study to down regulate allergic responses in adults with allergic rhinoconjunctivitis by using three intralymphatic injections of grass and birch allergen or plac...
    Medical condition: Allergic rhinoconjunctivitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006495-16 Sponsor Protocol Number: PrEPSo Start Date*: 2022-02-25
    Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
    Full Title: Immunogenicity and safety of Sotrovimab (Vir 7831) IV as primary prophylaxis in anti-SARS-CoV-2 vaccine non responders
    Medical condition: Covid 19 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084458 COVID-19 prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001943-60 Sponsor Protocol Number: SJF0001 Start Date*: 2011-06-20
    Sponsor Name:Lars Jørgen Østergaard
    Full Title: Cellular immunity in adult Hepatitis B-vaccinated serologic non-responders
    Medical condition: Healthy individuals
    Disease: Version SOC Term Classification Code Term Level
    13.1 10022891 - Investigations 10060023 Interferon gamma level PT
    13.1 10042613 - Surgical and medical procedures 10054130 Hepatitis B immunisation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001228-32 Sponsor Protocol Number: COV002 Start Date*: 2020-05-04
    Sponsor Name:CTRG
    Full Title: A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 22:19:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA